MDCO: The Medicines Company Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 4, 3:16 PM The Medicines Company (MDCO -1.4%) agrees to buy all of the outstanding capital stock of ProFibrix, subject to the company's satisfactory review of the pending Phase 3 clinical trial results of ProFibrix's lead biologic Fibrocaps. Under the terms of the agreement, MDCO will pay ProFibrix a $10M upfront option payment. If the company is satisfied with the trial results of the trial and decides to proceed, it will purchase all of the outstanding capital stock of ProFibrix at closing. Comment! [Healthcare, M&A, On the Move]
Wednesday, April 24, 8:07 AM The Medicines Co (MDCO): Q1 EPS of -$0.21 in-line. Revenue of $155.8M (+23% Y/Y) beats by $3.17M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 12:05 AM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Tuesday, April 23, 5:30 PM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Monday, March 11, 4:18 AM Medicines Co.'s (MDCO) blood thinner Cangrelor was 22% better at cutting heart risks following a stent procedure than the now generic clopidogrel (Plavix) in a wide-ranging trial. It's a bit of comeback for Cangrelor, which Medicines thought it would shelve in 2009 after disappointing earlier trials. However, follow-up studies showed it was better than Plavix. Medicines now plans to file for FDA approval for Cangrelor, which could generate estimated sales of $400M by 2019. (PR) Comment! [Healthcare]
Wednesday, February 20, 3:16 PM The Medicines Company (MDCO +6%) posts a big gain today after its Q4 easily topped estimates this morning. Revenue jumped by 20% Y/Y, boosted by a 77.2% jump in international sales of Angiomax/Angiox. Comment! [Healthcare, Earnings, On the Move]
Wednesday, February 20, 8:08 AM The Medicines Co (MDCO): Q4 EPS of $0.78 beats by $0.27. Revenue of $159.5M (+20.6% Y/Y) beats by $13.41M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 11, 11:00 AM Alnylam Pharmaceuticals (ALNY -3.4%) dips after MLV cut the shares to Hold from Buy. The firm says it prefers to take a cautious stance ahead of pending details of disease-modifying data from its lead partnered programs. One such program is its strategic alliance with The Medicines Co. (MDCO -3%) to develop ALN-PCS, an RNAi therapeutic program for the treatment of hypercholesterolemia. Comment! [Healthcare, On the Move]
Friday, February 8, 3:14 PM The Medicines Company (MDCO +0.6%) says its global license and two-year collaboration with Bristol-Myers (BMY +1.2%) for Recothrom, a recombinant thrombin approved by the FDA as a topical hemostat to control non-arterial bleeding during surgical procedures, has become effective. Comment! [Healthcare, On the Move]
Monday, February 4, 12:49 PM The Medicines Company (MDCO -1.5%) says it's formed an exclusive global alliance with Alnylam Pharmaceuticals (ALNY -2.6%) for the development and commercialization of ALNY's ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. The deal could net ALNY $205M plus double-digit royalties if the collaboration is successful, and an early-stage trial has already showed success. Comment! [Healthcare]
Monday, February 4, 8:22 AM The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from Alnylam Pharmaceuticals (ALNY), with Medicines paying $25M up front, as much as $180M in milestones, and then royalties. The treatment inhibits a protein called PCSK9 and is seen as an alternative to statins such as Lipitor. However, ALN-PCS is only in Phase I trials. Comment! [Healthcare]
Tuesday, January 8, 11:48 AM Medicines Co. (MDCO +10%) pushes through a 6-year high today as the stock surges after the drug maker announces positive Phase 3 trial results of its antiplatelet drug Cangrelor. Cangrelor demonstrated statistically significant improvement compared to clopidogrel, and MDCO intends to submit the results in the U.S. and E.U. for regulatory review in 2013. Comment! [Healthcare, On the Move]
Thursday, December 20, 2012, 3:31 PM Leerink ups its price target for The Medicines Co. (MDCO +7.1%) to $34 from $30 on the back of the drug developer's previously announced positive results for the Phase III trial of oritavancin. The firm now sees it as a takeout candidate and reiterates an Outperform. Separately, JPMorgan also ups the shares to Overweight. Comment! [On the Move, Healthcare]
Thursday, December 20, 2012, 8:44 AM Medicines Co's (MDCO) oritavancin drug for treating bacterial skin infections met the main goal of a Phase III trial by preventing the spread of the infection and without causing a fever. The study shows that one dose of oritavancin can cure infections, including MRSA, which is a particular problem in hospitals; oritavancin is also as effective as multiple days of infusions of the antibiotic vancomycin. (PR) Comment! [Healthcare]
Wednesday, December 12, 2012, 12:47 PM As a condition of Medicines Company's (MDCO +1.9%) acquisition of Incline Therapeutics, Cadence Pharmaceuticals (CADX +4.9%) has agreed to terminate its exclusive option to acquire Incline. Upon MDCO's closing of the deal, CADX will receive around $13M in termination fees and roughly $1.5M for its Incline stake as well as a pro-rated share of future milestone payments. Comment! [Healthcare, On the Move, M&A]
Wednesday, December 12, 2012, 12:37 PM Medicines Company (MDCO +1.9%) moves up today after agreeing to acquire privately held Incline Therapeutics for $185M plus potential milestone payments. The acquisition gives MDCO access to the development of a disposable and needleless patient-controlled analgesia system for postoperative pain management in hospitals. Additionally, the company also reached a licensing agreement with Bristol-Myers Squibb (BMY +0.6%) on its Recothrom topical treatment to control bleeding during surgery. Comment! [M&A, On the Move, Healthcare]

MDCO The Medicines Company

MDCO

The Medicines Company